EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Theragnostics","sponsor":"Ariceum Therapeutics","pharmaFlowCategory":"D","amount":"$44 million","upfrontCash":"$2.5 million","newsHeadline":"Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Theragnostics

    Menu

    Theragnostics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Theragnostics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd

              Details:

              The acquisition provides Ariceum with an expanded portfolio of therapeutic and diagnostic assets including, AT-001, a I-123-labelled PARP inhibitor for the treatment of aggressively growing cancers and it has UK ILAP approval for primary and recurrent glioblastoma.

              Lead Product(s): ATD-001

              Therapeutic Area: Oncology Product Name: ATD-001

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Ariceum Therapeutics

              Deal Size: $44 million Upfront Cash: $2.5 million

              Deal Type: Acquisition June 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY